Compound Radar

Progyny, Inc. (PGNY) Stock Analysis

United States · Healthcare / Healthcare Plans

Price $27.15
Market cap $2.08B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

58
58/100 Acceptable
  • Financial Health 70
  • Profitability 50
  • Business Quality 60
  • Balance Sheet 65
  • Cash Flow 50

Why this rating?

Health 58/100 — Acceptable

Strongest Financial Health 70/100
Softest Cash Flow 50/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Progyny, Inc. (PGNY) is a Healthcare Plans company in the Healthcare sector. Compound Radar rates Progyny, Inc. 58/100 (Acceptable) due to solid business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 29.51
  • Forward P/E 11.7
  • EV/Revenue 1.36

Profitability

  • Revenue Growth 5.3%
  • Gross Margin 24.6%
  • Operating Margin 11.4%
  • Net Margin 6.0%
  • ROE 16.2%

Financial strength

  • Cash $236.92M
  • Debt $22.50M
  • Net Cash $214.43M
  • Free Cash Flow $191.78M
  • Current Ratio 2.14

Similar companies

Peers in Healthcare Plans, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Healthcare Plans →

FAQ

How Compound Radar scores and tracks Progyny, Inc. (PGNY).

View Methodology & FAQ →